Related Experiment Video
Updated: Jul 5, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Summary
Xemilofiban, an oral antiplatelet agent, shows promise in preventing blood clots after angioplasty. Clinical trials are evaluating its effectiveness in reducing cardiac events and the need for revascularization procedures.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Xemilofiban is an orally-active glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist.
- It is under development for preventing thrombotic complications after percutaneous transluminal coronary angioplasty (PTCA).
Purpose of the Study:
- To evaluate the cardiovascular benefits of xemilofiban in a large-scale phase III trial (EXCITE).
- To assess the reduction of clot-related cardiac events, such as heart attack and death, and the need for revascularization procedures after angioplasty or stent placement.
Main Methods:
- Phase III EXCITE trial enrolling approximately 7200 patients undergoing angioplasty or stent placement.
- Phase II ORBIT trial demonstrated inhibition of platelet aggregation.
- Phase I studies in Japan evaluated patients undergoing coronary revascularization.
Main Results:
- Phase II ORBIT trial showed four-week xemilofiban therapy inhibited platelet aggregation by 50-80%.
- Preliminary studies indicate rapid inhibition of ADP and collagen-induced platelet aggregation.
- Mechanism involves potent inhibition of platelet aggregation via GPIIb/IIIa antagonism.
Conclusions:
- Xemilofiban is a potent and selective GPIIb/IIIa inhibitor with potential cardiovascular benefits.
- Ongoing trials are evaluating its efficacy in preventing thrombotic events post-PTCA and in heart attack patients.
- Expected launch for angioplasty is 2000, followed by unstable angina and acute myocardial infarction (AMI).
Related Concept Videos
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...